214 results
6-K
EX-99.1
BLU
Bellus Health Inc
19 May 23
Current report (foreign)
5:27pm
performed by the FDA or otherwise has jurisdiction over the safety, efficacy, approval, development, testing, labeling, manufacturing, storage, marketing
6-K
EX-99.2
BLU
Bellus Health Inc
12 May 23
Condensed Consolidated Interim Financial Statements of
4:32pm
with GSK and the timeline expected in respect thereof;
the function, potential benefits, effectiveness and safety of camlipixant;
the accuracy of our … evaluating the efficacy, safety and tolerability of camlipixant in RCC. Both trials are running concurrently, and each will recruit approximately 675 adult
6-K
EX-99.1
BLU
Bellus Health Inc
12 May 23
BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights
4:02pm
development of its P2X3 receptor pipeline.
BELLUS Health reported positive results from its Phase 1 clinical trial investigating the safety … bioavailability to the twice-daily Immediate Release (“IR”) formulation. In addition, the ER formulation was well tolerated, with safety data observed
6-K
EX-99.2
BLU
Bellus Health Inc
27 Apr 23
Material Change Report
6:04am
) quality, safety and accreditation standards and requirements of all applicable Governmental Bodies, (x) all Laws pursuant to which permits relating … been excluded from government health care programs, quality, safety, privacy, security, licensure, accreditation or any other aspect of providing health
6-K
EX-99.1
BLU
Bellus Health Inc
5 Apr 23
BELLUS Health Announces Positive Results from its Phase 1 Bioavailability Equivalence Study Evaluating
7:01am
formulation was well tolerated, with the safety profile consistent with previous camlipixant trials and no taste-related adverse events reported
Additional … formulation was well tolerated, with the safety profile consistent with previous camlipixant trials and no taste-related adverse events reported
6-K
EX-99.1
k9dk0 hr0cl
29 Mar 23
Current report (foreign)
5:26pm
6-K
EX-99.2
buragel4
14 Nov 22
Condensed Consolidated Interim Financial Statements of
5:26pm
SUPPL
d9z l5k5zhv1
14 Nov 22
Supplemental materials (foreign)
5:25pm
6-K
EX-99.1
qcz46a1
14 Nov 22
Open Market Sale Agreementsm
5:19pm
6-K
EX-99.1
kqqurtdxlyagu4p
16 Sep 22
Investor Presentation NASDAQ/TSX - BLU September 16 th , 2022
4:40pm
F-10
mnmt o72zde5zudb
26 Aug 22
Registration of securities (Canada)
4:48pm
6-K
EX-99.2
16wy0l0wka 1egrd68zu
10 Aug 22
Condensed Consolidated Interim Financial Statements of
4:56pm
SUPPL
swv8 rwwdci8cfw
15 Jul 22
Supplemental materials (foreign)
7:01am
6-K
EX-99.2
sn6v 5x85ie5j
14 Jul 22
BELLUS Health Announces Pricing of US$153 Million Public Offering in Canada and the United States
4:46pm
SUPPL
1ts4gvs77
13 Jul 22
Supplemental materials (foreign)
5:01pm
6-K
EX-99.2
scsp490q4afmxl
13 Jul 22
BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States
4:25pm
6-K
EX-99.2
7fhyd8wnhyefqsvbu
12 Jul 22
Bellus Health Announces Positive End-of-Phase 2 Meeting with the FDA and its CALM Phase 3 Program for BLU-5937 in Refractory Chronic Cough
7:27am
6-K
EX-99.1
os762 4jn04
12 Jul 22
Bellus Health Announces Positive End-of-Phase 2 Meeting with the FDA and its CALM Phase 3 Program for BLU-5937 in Refractory Chronic Cough
7:27am
6-K
EX-99.1
24pwq3uvt
11 May 22
BELLUS Health Reports First Quarter 2022 Financial Results and Business Highlights
5:23pm
6-K
EX-99.2
unl15h50mb ekpupxq
11 May 22
Condensed Consolidated Interim Financial Statements of
5:05pm